J 2019

Growth differentiation factor-15 and all-cause mortality in patients with suspected myocardial infarction

WALTER, Joan, Thomas NESTELBERGER, Jasper BOEDDINGHAUS, Raphael TWERENBOLD, Lukas CROTON et. al.

Basic information

Original name

Growth differentiation factor-15 and all-cause mortality in patients with suspected myocardial infarction

Authors

WALTER, Joan (756 Switzerland), Thomas NESTELBERGER (756 Switzerland), Jasper BOEDDINGHAUS (756 Switzerland), Raphael TWERENBOLD (756 Switzerland), Lukas CROTON (756 Switzerland), Patrick BADERTSCHER (756 Switzerland), Karin WILDI (756 Switzerland), Desiree WUSSLER (756 Switzerland), Jeanne du Fay DE LAVALLAZ (756 Switzerland), Christian MUELLER (756 Switzerland, guarantor), Maria Rubini GIMENEZ (756 Switzerland), Christian PUELACHER (756 Switzerland), Nikola KOZHUHAROV (756 Switzerland), Beata MORAWIEC (756 Switzerland), Katharina RENTSCH (756 Switzerland), Oscar MIRO (756 Switzerland), F. Javier MARTIN-SANCHEZ (756 Switzerland), Piotr MUZYK (756 Switzerland), Nicolas GEIGY (756 Switzerland), Dagmar I. KELLER (756 Switzerland), Tobias REICHLIN (756 Switzerland), Jens LOHRMANN (756 Switzerland), Ewalina BISKUP (756 Switzerland), Wanda KLOOS (756 Switzerland), Beatriz LOPEZ (724 Spain), Carolina Fuenzalida INOSTROZA (724 Spain), Esther Rodriguez ADRADA (724 Spain), Damian KAWECKI (616 Poland), Piotr MUZYK (616 Poland), Ewa NOWALANY-KOZIELSKA (616 Poland), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Kathrin MEISSNER (756 Switzerland), Caroline KULANGARA (756 Switzerland), Riham MAHFOUZ (756 Switzerland), Katharina RENTSCH (756 Switzerland) and Arnold VON ECKARDSTEIN (756 Switzerland)

Edition

International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2019, 0167-5273

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.229

RIV identification code

RIV/00216224:14110/19:00110562

Organization unit

Faculty of Medicine

UT WoS

000476878000050

Keywords in English

Biomarkers; Acute coronary syndromes; Mortality/survival

Tags

Tags

International impact, Reviewed
Změněno: 3/9/2019 10:15, Mgr. Tereza Miškechová

Abstract

V originále

Background: To assess the prognostic performance of Growth differentiation factor-15 (GDF-15) concentrations in unselected patients presenting with suspected acute myocardial infarction (AMI) and adjudication based on high-sensitivity cardiac troponin (hs-cTn). Methods and results: In an ongoing prospective multicenter diagnostic study, consecutive patients presenting with suspected AMI to the emergency department and available GDF-15 and hs-cTnT concentrations were included. Adjudication of AMI was performed central by two independent cardiologists using all available clinical information including cardiac imaging and serial hs-cTn concentrations. Overall, 718 patients were included, with 23% (162/718) having an adjudicated diagnosis of AMI. The cumulative incidence of death within 2 years was 19% in patients with AMI (30 deaths in 162 patients) versus 5% in patients without AMI (25 deaths in 556 patients; P < 0.001). In AMI patients, GDF-15 provided an AUC of 0.89 (95% confidence interval [CI] 0.83-0.94) for 2-year death versus 0.55 (95% CI 0.44-0.66) for hs-cTnT (P < 0.001). A GDF-15 cutoff of <= 1560 ng/L predicted 2-year survival in 47% (76/162) of AMI patients and had 100% sensitivity (95% CI 88-100%) for 2-year death. In patients without AMI, GDF-15 provided an AUC of 0.83 (95% CI 0.76-0.89) versus 0.76 (95% CI 0.67-0.85) for hscTnT (P= 0.096). A GDF-15 cutoff of <= 886 ng/L predicted 2-year survival in 37% (203/556) of non-AMI patients and had 100% sensitivity (95% CI 86-100%) for 2-year death. Conclusions: GDF-15 concentrations at emergency department presentation have a high predictive accuracy for all-cause death in patients with suspected AMI and allow the identification of a large proportion of AMI patients with very low mortality risk. (C) 2019 Elsevier B.V. All rights reserved.